|
End-of-day quote
Korea S.E.
2026-10-08
|
5-day change | 1st Jan Change | ||
| 17,320.00 KRW | -5.04% |
|
-4.04% | -69.83% |
| 07-23 | Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell | MT |
| 12-21 | IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index | CI |
Company Valuation: IntoCell, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2025 |
|---|---|
| Market Cap 1 | 861,052 |
| Change | - |
| Enterprise Value (EV) 1 | 840,466 |
| Change | - |
| P/E | -77.1x |
| PBR | 34.8x |
| PEG | 48.66x |
| Capitalization / Revenue | 374,513,177x |
| EV / Revenue | - |
| EV / EBITDA | -88.2x |
| EV / EBIT | -81.6x |
| EV / FCF | -132x |
| FCF Yield | -0.76% |
| Dividend per Share 2 | - |
| Rate of return | - |
| EPS 2 | -744 |
| Distribution rate | - |
| Net sales | 2,299 |
| EBITDA 1 | -9,526 |
| EBIT 1 | -10,300 |
| Net income 1 | -10,603 |
| Net Debt 1 | -20,586 |
| Reference price 2 | 57,400.00 |
| Nbr of stocks (in thousands) | 15,001 |
| Announcement Date | 3/1/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 194M | |
| 20.5x | 7.3x | 14.66x | 1.45% | 70.61B | |
| 27.46x | 7.51x | 23.56x | 0.05% | 51.01B | |
| 33.37x | 6x | 17.96x | 0.97% | 48.1B | |
| 33.47x | 3.25x | 14.03x | -.--% | 42.78B | |
| -19.64x | 203.45x | -20.92x | -.--% | 40.67B | |
| 46.95x | 5.34x | 29.33x | -.--% | 40.3B | |
| 27.18x | 7.73x | 20.09x | 0.42% | 30.59B | |
| 32.53x | 6.94x | 18.03x | -.--% | 28.16B | |
| -14.69x | 5.97x | -7.21x | -.--% | 24.36B | |
| Average | 20.79x | 28.17x | 12.17x | 0.32% | 37.68B | |
| Weighted average by Cap. | 22.22x | 27.60x | 13.22x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A287840 Stock
- Valuation IntoCell, Inc.
Select your edition
All financial news and data tailored to specific country editions
